Atc stock trial#

Atc stock trial#

The study was an adaptive trial designed to assess the potential of new therapeutics to treat the highly aggressive brain cancer glioblastoma (GBM) in a cost-effective manner. Kazia Therapeutics (KZA) announced yesterday morning that paxalisib did not meet the threshold to move into stage 2 of the GBM AGILE clinical trial (NCT03970447). Cash on hand of $3.6m (2QįY23) is likely sufficient to fund operations until breakeven is reached.ĭOWNLOAD RESEARCH REPORT Paxalisib Misses AGILE Hurdle, but Very Significant Value Remains Investors Over-React, Smart Ones Will Profit Represents sufficient scale to reach profitability. The company has built a significant new contract pipeline in recent quartersĪnd is targeting c.15,000 subscribers on its platform by Dec 2023, which

There is a growing recurring revenueĬomponent built on SaaS-based subscriptions to its platform. The market is very fragmented, with no competitor offering CTQ’sĬTQ’s income stream is non-discretionary and largely funded by federal and Technology innovation and recommendations from the Royal Commission intoĪged Care. Products, driven by the ageing population, rising costs and labour shortages, The health-tech industry enjoys significant tailwinds for assistive living Include falls detection, vital signs monitoring and medication management. Home care, disability care and personal security sectors. (Sofihub) with a portfolio of best-in-class solutions for the global aged care, CTQ has developed a leading proprietary assistive living technology platform